Welcome to our dedicated page for Sionna Therapeutics news (Ticker: SION), a resource for investors and traders seeking the latest updates and insights on Sionna Therapeutics stock.
Sionna Therapeutics (SION) is a clinical-stage biopharmaceutical company advancing novel therapies for cystic fibrosis through targeted CFTR protein modulation. This page provides investors and healthcare stakeholders with timely updates on the company's scientific progress, including clinical developments, regulatory milestones, and research breakthroughs.
Access consolidated updates on Sionna's pipeline of small molecule therapies designed to stabilize the CFTR protein's NBD1 domain—a critical approach addressing the root cause of CF in patients with F508del and other mutations. Our news collection covers essential updates including trial results, partnership announcements, and peer-reviewed research publications.
Key content areas include progress reports on complementary CFTR modulators, preclinical-to-clinical transitions, and strategic initiatives within the competitive CF treatment landscape. Bookmark this page to stay informed about Sionna's contributions to advancing precision medicine for genetic respiratory diseases.
Sionna Therapeutics (Nasdaq: SION) presented Phase 1 clinical and new preclinical data at the 2025 North American Cystic Fibrosis Conference on Oct 24, 2025. Two first‑in‑class NBD1 stabilizers, SION-719 and SION-451, were generally well tolerated in >200 healthy volunteers and exceeded pharmacokinetic targets. Phase 1 results supported a tablet formulation and dosing in fed or fasted states. New preclinical pulse‑chase data showed NBD1 stabilizers increased the half‑life of F508del‑CFTR protein to levels comparable to wild‑type CFTR, an effect seen even as single agents. The company noted a Phase 2a proof‑of‑concept study is underway with readouts expected in mid‑2026.
Sionna Therapeutics (Nasdaq: SION) initiated the PreciSION CF Phase 2a randomized, double-blind, placebo-controlled crossover trial of SION-719, a first-in-class NBD1 stabilizer, added to Trikafta as standard of care in adults homozygous for F508del with cystic fibrosis. The trial will assess safety, tolerability, PK and change in CFTR function measured by sweat chloride. Topline data are anticipated in mid-2026. Earlier Phase 1 data showed SION-719 was generally well tolerated and exceeded PK targets; a drug-drug interaction study with midazolam supported dosing with Trikafta.
Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), will present data at the 2025 North American Cystic Fibrosis Conference (NACFC) in Seattle from October 22-25, 2025.
The company will showcase two presentations: a workshop discussing safety and pharmacokinetics data from Phase 1 trials of their novel NBD1 stabilizers SION-719 and SION-451, and a poster presentation about small molecule stabilizers' effects on F508del-CFTR. Both presentations will be available on Sionna's website under the Scientific Presentations section.
Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), has appointed Caroline Stark Beer, MBA as Chief Business Officer. Beer brings over 20 years of life science industry experience, most recently serving as CBO at Jnana Therapeutics until its acquisition by Otsuka Pharmaceutical.
Beer's previous experience includes a decade at Alnylam Pharmaceuticals where she served as VP of Business Development, leading significant partnerships including a 5-year collaboration with Regeneron Pharmaceuticals. She holds an MBA from MIT Sloan School of Management and previously worked at Amicus Therapeutics and Bain & Company.
Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, has announced its participation in two major healthcare investor conferences in September 2025.
The company will participate in fireside chats at the Cantor Global Healthcare Conference on September 3rd at 1:35 p.m. ET and the Morgan Stanley Global Healthcare Conference on September 8th at 7:00 a.m. ET. Both events will be held in New York and will be available via webcast on the company's investor relations website.
Sionna Therapeutics (NASDAQ:SION) has initiated dosing in a Phase 1 trial evaluating SION-451, their first-in-class NBD1 stabilizer, in dual combinations with SION-2222 and SION-109 for cystic fibrosis treatment. The randomized, double-blind, placebo-controlled trial in healthy volunteers will assess safety, tolerability, and pharmacokinetics of these combinations.
The study targets cystic fibrosis, a genetic disease affecting over 100,000 people globally. The trial's significance lies in SION-451 being the first NBD1-anchored treatment approach, with topline data expected in mid-2026. Previous Phase 1 trials showed SION-451 was generally well-tolerated and achieved PK concentration targets suggesting potential clinical benefits, including possible wild-type levels of CFTR function.
Sionna Therapeutics (NASDAQ:SION) reported Q2 2025 financial results and provided key updates on its cystic fibrosis (CF) drug development programs. The company announced positive Phase 1 data for its first-in-class NBD1 stabilizers, SION-719 and SION-451, which demonstrated favorable tolerability and exceeded pharmacokinetic targets.
The company plans to initiate a Phase 2a proof-of-concept trial for SION-719 as an add-on therapy in H2 2025, with topline data expected mid-2026. Additionally, SION-451 will advance to Phase 1 trials in dual combinations. Financially, Sionna reported a net loss of $18.1 million and maintains a strong cash position of $337.3 million, expected to fund operations into 2028.
FAQ
What is the current stock price of Sionna Therapeutics (SION)?
What is the market cap of Sionna Therapeutics (SION)?
